| Not Yet Recruiting | A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects NCT07099118 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Recruiting | Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial NCT06138821 | Pichamol Jirapinyo, MD, MPH | N/A |
| Completed | Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants NCT06716905 | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 |
| Recruiting | Identification of Liver Fibrosis Biomarkers NCT06819917 | Roche Diagnostics GmbH | — |
| Not Yet Recruiting | Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for NCT06160271 | Central Hospital, Nancy, France | Phase 2 |
| Recruiting | Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatiti NCT06676813 | Institute of Liver and Biliary Sciences, India | N/A |
| Enrolling By Invitation | Reducing Non-Alcoholic Steatohepatitis NCT06519448 | Military University Hospital, Prague | N/A |
| Completed | Ultrasound and Attenuation Imaging NCT06552377 | Hywel Dda Health Board | — |
| Completed | Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis NCT06105060 | Beni-Suef University | EARLY_Phase 1 |
| Completed | A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) NCT06052566 | Merck Sharp & Dohme LLC | Phase 1 |
| Withdrawn | Assessment of Fatty Liver With Thermo-acoustic Device NCT04302051 | Medical College of Wisconsin | — |
| Unknown | Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory NCT05751720 | Dr Adnan Agha | Phase 1 / Phase 2 |
| Completed | Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH NCT06054815 | NeuroBo Pharmaceuticals Inc. | Phase 2 |
| Recruiting | Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjec NCT06569524 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Study of INI-822 in Healthy Volunteers and Participants with Non-alcoholic Steatohepatitis (NASH) or Presume NCT05945537 | Inipharm Australia Pty Ltd | Phase 1 |
| Unknown | the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis. NCT05942547 | Tanta University | Phase 3 |
| Completed | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Ad NCT05848440 | AstraZeneca | Phase 1 |
| Completed | A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic I NCT05835180 | Sagimet Biosciences Inc. | Phase 1 |
| Recruiting | InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer NCT05463796 | Dana-Farber Cancer Institute | — |
| Recruiting | Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis NCT05821010 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 |
| Completed | A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combinatio NCT05766709 | Novo Nordisk A/S | Phase 1 |
| Completed | Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH NCT06297434 | J2H Biotech | Phase 2 |
| Terminated | A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants NCT05668936 | AstraZeneca | Phase 1 |
| Completed | Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females NCT06308874 | J2H Biotech | Phase 1 |
| Recruiting | CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome NCT05623150 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Unknown | Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcohol NCT05605158 | Tanta University | Phase 3 |
| Active Not Recruiting | Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH NCT05462353 | Gannex Pharma Co., Ltd. | Phase 2 |
| Recruiting | Soluble Fibre Supplementation in NAFLD NCT05480696 | McMaster University | Phase 2 |
| Active Not Recruiting | Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuric NCT05574036 | Tanta University | Phase 2 |
| Unknown | Omics-based Predictors of NAFLD/Potential NASH NCT05301231 | National Research Centre, Egypt | — |
| Unknown | First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass In NCT05517564 | JD Bioscience Inc. | Phase 1 |
| Completed | Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis NCT05254626 | Cairo University | Phase 2 |
| Unknown | Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis NCT03803540 | Puerta de Hierro University Hospital | Phase 1 |
| Completed | Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH NCT05357248 | Better Therapeutics | N/A |
| Completed | A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy NCT05294458 | AstraZeneca | Phase 1 |
| Completed | Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease NCT04182646 | Asian Institute of Gastroenterology, India | N/A |
| Completed | A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants NCT05053165 | LISCure Biosciences | Phase 1 |
| Completed | A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Al NCT05397379 | Sunshine Lake Pharma Co., Ltd. | Phase 2 |
| Active Not Recruiting | The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis NCT05065593 | Hacettepe University | N/A |
| Active Not Recruiting | Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis NCT05573204 | Tanta University | Phase 2 |
| Completed | Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non NCT05016882 | Novo Nordisk A/S | Phase 2 |
| Unknown | MLCT Oil for Fatty Liver - PASS Trial NCT05217745 | National University Hospital, Singapore | N/A |
| Completed | Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis NCT04669158 | Stanford University | Phase 1 / Phase 2 |
| Completed | Mobile Health Delivered Lifestyle Intervention Program in Patients With NASH NCT04872777 | Milton S. Hershey Medical Center | N/A |
| Recruiting | Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease NCT05728697 | Brigham and Women's Hospital | — |
| Completed | The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects NCT04829123 | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | Phase 1 |
| Completed | A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy V NCT04931147 | Redx Pharma Ltd | Phase 1 |
| Active Not Recruiting | Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) NCT04822181 | Novo Nordisk A/S | Phase 3 |
| Unknown | Plant Stanols and Liver Inflammation in Overweight and Obese Children NCT04783116 | Maastricht University Medical Center | N/A |
| Completed | Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study NCT04800094 | Philips Clinical & Medical Affairs Global | N/A |
| Completed | A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men NCT04722653 | Novo Nordisk A/S | Phase 1 |
| Withdrawn | Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis NCT03962608 | Yaqrit Ltd | N/A |
| Recruiting | "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors NCT04690972 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Completed | Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD. NCT04579874 | Fibronostics USA, Inc | N/A |
| Completed | Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study NCT04657523 | Philips Clinical & Medical Affairs Global | N/A |
| Recruiting | Integrated Diagnostics for Early Diagnosis of Liver Disease NCT04666402 | Manchester University NHS Foundation Trust | — |
| Recruiting | The Olmsted NAFLD Epidemiology Study (TONES) NCT04365855 | Mayo Clinic | N/A |
| Terminated | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participa NCT04171765 | Genentech, Inc. | Phase 2 |
| Completed | The Role of Immune Semaphorins in NAFLD NCT04573543 | University Hospital for Infectious Diseases, Croatia | — |
| Completed | Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males NCT06308861 | J2H Biotech | Phase 1 |
| Completed | The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects NCT04422496 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Unknown | Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease NCT06176079 | Michael Ohliger, MD PhD | — |
| Unknown | To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patien NCT03950505 | Yonsei University | Phase 4 |
| Completed | Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NAS NCT04202354 | Arrowhead Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Pr NCT04378010 | Enanta Pharmaceuticals, Inc | Phase 2 |
| Completed | Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (P NCT04198805 | Naga P. Chalasani | Phase 2 |
| Withdrawn | NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Rev NCT03864835 | Milton S. Hershey Medical Center | N/A |
| Completed | A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, NCT04142424 | AstraZeneca | Phase 1 |
| Completed | Glucagon Resistance in Patients With NAFLD NCT04042142 | University of Aarhus | N/A |
| Completed | Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH) NCT04537780 | Tanta University | Phase 4 |
| Recruiting | Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD NCT03884075 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alc NCT03969719 | Pfizer | Phase 2 |
| Terminated | Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis NCT03883607 | Genfit | Phase 2 |
| Completed | A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage NCT03987451 | Novo Nordisk A/S | Phase 2 |
| Completed | Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis NCT03863574 | Zydus Therapeutics Inc. | Phase 2 |
| Completed | Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis NCT05357352 | Methodist Health System | — |
| Withdrawn | Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver NCT03437720 | Sanofi | Phase 2 |
| Unknown | Investigation on the Role of Gut-liver Axis for Non-alcoholic Steatohepatitis Through Bariatric Surgery NCT04501042 | National Taiwan University Hospital | — |
| Completed | Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver NCT03839082 | University of Michigan | N/A |
| Completed | Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis ( NCT03812029 | Enyo Pharma | Phase 2 |
| Completed | Bariatric Surgery Versus Non-alcoholic Steato-hepatitis NCT03524365 | Catholic University of the Sacred Heart | N/A |
| Completed | An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis NCT03656068 | Pinnacle Clinical Research, PLLC | Phase 2 |
| Completed | Expanding Donor Pool for Live Donor Liver Transplantation: Utilization of Donors With NASH After Optimization NCT04571957 | Institute of Liver and Biliary Sciences, India | — |
| Recruiting | Prognostic Significance of Fatty Liver Disease in Bariatric Patients NCT03535142 | Esbjerg Hospital - University Hospital of Southern Denmark | N/A |
| Completed | Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steato NCT03664596 | Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan | N/A |
| Completed | 2-Week Study In People With Nonalcoholic Fatty Liver Disease NCT03513588 | Pfizer | Phase 1 |
| Completed | Technical Validation of MR Biomarkers of Obesity-Associated NAFLD NCT03674528 | University of Wisconsin, Madison | — |
| Completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alco NCT03421431 | Enanta Pharmaceuticals, Inc | Phase 2 |
| Unknown | The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty NCT03734510 | National Nutrition and Food Technology Institute | N/A |
| Completed | Coffee Consumption and NASH in the French Population. NCT03432377 | Versailles Hospital | — |
| Recruiting | European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD) NCT04190849 | Cambridge University Hospitals NHS Foundation Trust | — |
| Unknown | Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis NCT03198572 | Fudan University | Phase 4 |
| Completed | Repeatability and Reproducibility of Multiparametric MRI NCT03743272 | Perspectum | — |
| Unknown | The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver NCT03377153 | National Nutrition and Food Technology Institute | N/A |
| Unknown | The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease NCT03377140 | National Nutrition and Food Technology Institute | N/A |
| Completed | EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity NCT02880189 | Mayo Clinic | N/A |
| Completed | Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placeb NCT02970942 | Novo Nordisk A/S | Phase 2 |
| Terminated | Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) NCT02787304 | Mirum Pharmaceuticals, Inc. | Phase 2 |
| Completed | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) NCT02912260 | Madrigal Pharmaceuticals, Inc. | Phase 2 |
| Completed | Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension NCT02960204 | Histogen | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH NCT02784444 | Cirius Therapeutics, Inc. | Phase 2 |
| Completed | Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI NCT03198104 | Perspectum | — |
| Unknown | Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis. NCT02721264 | Institute of Liver and Biliary Sciences, India | N/A |
| Completed | Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects NCT02681055 | MediciNova | Phase 2 |
| Completed | Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis NCT02686762 | Conatus Pharmaceuticals Inc. | Phase 2 |
| Unknown | Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis NCT01617772 | Tehran University of Medical Sciences | Phase 2 |
| Completed | A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose NCT02571192 | Mirum Pharmaceuticals, Inc. | Phase 1 |
| Completed | The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis NCT02528305 | University of Bath | N/A |
| Terminated | The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults NCT03142867 | The Geneva Foundation | — |
| Withdrawn | Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepat NCT02541045 | Hospital General de Mexico | Phase 3 |
| Completed | A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) NCT02413372 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) NCT03400163 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NAS NCT02279524 | Galmed Research and Development, Ltd. | Phase 2 |
| Completed | Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin NCT02235233 | University of North Carolina, Chapel Hill | Phase 1 |
| Completed | BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH NCT02314026 | Meridian Bioscience, Inc. | Phase 2 |
| Completed | Safety and Tolerability Study of SHP626 in Overweight and Obese Adults NCT02287779 | Mirum Pharmaceuticals, Inc. | Phase 1 |
| Unknown | The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis NCT02530138 | National Nutrition and Food Technology Institute | Phase 2 / Phase 3 |
| Completed | The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic F NCT02395900 | National Nutrition and Food Technology Institute | Phase 2 / Phase 3 |
| Completed | The Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepat NCT02231333 | Institute of Liver and Biliary Sciences, India | N/A |
| Unknown | Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD NCT02075164 | Prof. Michael Trauner, MD | N/A |
| Completed | Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis NCT01766713 | University of California, San Diego | Phase 2 |
| Completed | Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients NCT01695083 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic NCT01791959 | National Nutrition and Food Technology Institute | Phase 2 / Phase 3 |
| Completed | Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pil NCT01696487 | Medical University of Vienna | N/A |
| Withdrawn | Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Ra NCT01279434 | Institute of Liver and Biliary Sciences, India | N/A |
| Withdrawn | Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis NCT01384578 | Institute of Liver and Biliary Sciences, India | Phase 3 |
| Completed | Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls NCT01674972 | University Hospital, Basel, Switzerland | — |
| Completed | The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis NCT01278056 | Crolll Gmbh | Phase 1 / Phase 2 |
| Completed | Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH) NCT01056133 | Johane Allard | Phase 2 |
| Completed | The Effect of Protandim on Non-alcoholic Steatohepatitis NCT00977730 | University of Colorado, Denver | N/A |
| Terminated | Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocyto NCT00678587 | GlaxoSmithKline | Phase 3 |
| Withdrawn | Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children NCT00677183 | Medical College of Wisconsin | — |
| Completed | Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis NCT00680407 | Madaus Inc | Phase 2 |
| Completed | A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9 NCT00668070 | Astellas Pharma Inc | Phase 2 |
| Completed | Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) NCT00681408 | University of Virginia | Phase 2 / Phase 3 |
| Completed | Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH) NCT01761370 | National University Hospital, Singapore | N/A |
| Completed | A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatit NCT00492700 | Association pour la Recherche sur les Maladies Hépatiques Virales | Phase 2 |